HC Wainwright Forecasts Weaker Earnings for Delcath Systems

Delcath Systems, Inc. (NASDAQ:DCTH) – Analysts at HC Wainwright dropped their FY2029 earnings per share (EPS) estimates for Delcath Systems in a research note issued to investors on Monday, March 2nd. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $1.92 per share for the year, down from their previous forecast of $2.21. HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Delcath Systems’ current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Delcath Systems’ FY2030 earnings at $2.68 EPS.

DCTH has been the topic of several other research reports. Evercore set a $27.00 price target on shares of Delcath Systems in a research report on Thursday, February 26th. Stephens dropped their target price on Delcath Systems from $25.00 to $18.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Delcath Systems in a research report on Monday, December 29th. BTIG Research lowered their price target on Delcath Systems from $23.00 to $19.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Finally, Wall Street Zen cut Delcath Systems from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $22.50.

Delcath Systems Trading Up 7.3%

Delcath Systems stock opened at $9.23 on Tuesday. The firm has a market capitalization of $320.74 million, a price-to-earnings ratio of 131.86 and a beta of 0.38. The firm’s fifty day moving average price is $9.91 and its two-hundred day moving average price is $10.16. Delcath Systems has a 1-year low of $8.12 and a 1-year high of $18.23.

Delcath Systems (NASDAQ:DCTH) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. The business had revenue of $20.73 million during the quarter, compared to the consensus estimate of $20.35 million. Delcath Systems had a net margin of 3.17% and a return on equity of 2.63%.

Delcath Systems declared that its board has approved a share buyback program on Thursday, November 20th that authorizes the company to repurchase $25.00 million in shares. This repurchase authorization authorizes the company to buy up to 8.6% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Institutional Investors Weigh In On Delcath Systems

A number of hedge funds have recently made changes to their positions in the business. XTX Topco Ltd increased its stake in Delcath Systems by 339.4% in the 4th quarter. XTX Topco Ltd now owns 71,193 shares of the company’s stock worth $719,000 after acquiring an additional 54,990 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Delcath Systems by 3.0% during the fourth quarter. Millennium Management LLC now owns 246,444 shares of the company’s stock worth $2,489,000 after purchasing an additional 7,190 shares in the last quarter. Man Group plc increased its position in shares of Delcath Systems by 34.1% in the fourth quarter. Man Group plc now owns 38,158 shares of the company’s stock worth $385,000 after purchasing an additional 9,705 shares during the last quarter. Balyasny Asset Management L.P. raised its stake in Delcath Systems by 69.5% in the fourth quarter. Balyasny Asset Management L.P. now owns 52,140 shares of the company’s stock valued at $527,000 after purchasing an additional 21,384 shares in the last quarter. Finally, Jump Financial LLC lifted its position in Delcath Systems by 68.0% during the fourth quarter. Jump Financial LLC now owns 45,953 shares of the company’s stock valued at $464,000 after purchasing an additional 18,596 shares during the last quarter. 61.12% of the stock is currently owned by institutional investors.

Delcath Systems News Roundup

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Publication of CHOPIN Phase 2 trial in The Lancet Oncology — The full, investigator‑initiated CHOPIN randomized Phase 2 results led by Prof. Ellen Kapiteijn were published, increasing clinical visibility and credibility for Delcath’s liver‑directed chemotherapy platform; this type of high‑profile peer‑reviewed publication can support investor confidence and future regulatory/commercial discussions. Article Title Business Wire Release
• Neutral Sentiment: HC Wainwright maintains a Buy rating and a $30 price target — the firm continues to show long‑term conviction even as it revises near‑term numbers, which may temper negative reactions relative to a full downgrade.
• Neutral Sentiment: Long‑range forecasts mixed — HC Wainwright published multi‑year model estimates (including a new FY2030 EPS projection), showing a path to profitability further out; these farther‑out estimates are informative but less likely to move the stock as much as near‑term revisions.
• Neutral Sentiment: Short interest report shows no meaningful data change — the reported short interest figures appear to be zero/erroneous and do not indicate increased short pressure at this time.
• Negative Sentiment: Multiple downward EPS revisions from HC Wainwright — the analyst cut Q1–Q4 2026 and FY2026 estimates significantly (examples: Q1 from $0.13 to ($0.01), Q2 from $0.08 to ($0.15), Q3 from $0.10 to ($0.42), and FY2026 from $0.58 to ($0.86)), and lowered FY2027‑FY2029/FY2028/FY2029 forecasts as well. Those near‑term cuts increase uncertainty about upcoming quarters and could limit upside despite the trial publication.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.